Recently，Non -prescription drug sales leader and Pharmaceutical Announcement Orientation Plan (hereinafter referred to as "Plan")，It is planned to issue a price orientation of not less than 18.36 yuan per share and not more than 50 million shares，It is expected to raise about 900 million yuan，It is used to acquire all equity of Camphor Pharmaceutical and Jiangxi Pharmaceutical Metropolis Pharmaceutical、70%equity of Jiangxi Pharmaceuticals and 55%equity of Ren and Pharmaceutical Plastic Products。

If the plan is passed，Renhe Pharmaceutical will get 4 subsidiaries again，The first step of the two -track development mode of OTC and prescription drugs，Complete the 5th mergers and acquisitions of more than a year，And these mergers and acquisitions will also open the prelude to integrate mergers and acquisitions in the domestic drug field。　　

 

OTC leader entered the prescription medicine

 

Renhe Pharmaceutical has been conducting relevant asset mergers and acquisitions in recent years，From July 2009 to the present, I have completed Kangmei stake sports betting appMy stake betting appMedicine、Yaomu Renhe、Acquisition of Aerospace Tyls and Shining Pharmaceuticals。

 

The purpose of this addition and mergers and acquisitions this time is similar to the past，Mainly to enrich the category and broaden the business scope，Enhance the motivation for subsequent development of the enterprise。Announcement display，Zhangshu Pharmaceutical and Pharmaceutical Pharmaceuticals are subsidiaries of Zhangshu Pharmaceutical Group，The former is responsible for production，With 230 varieties，Among them, 13 Chinese medicine protection varieties，The main variety is the great vitality pill，The latter is responsible for sales; the acquisition of Renhe Pymaline plastic products is to complete the promise of Renhe Group in December 2010。

 

Another company to be acquired is Jiangxi Pharmaceutical，It mainly focuses on the production and sales of prescription drugs，337 varieties owned by the national drug production approval number，There are 125 kinds of entering the country's basic drug directory，The main products are sulfate sulfenicin、Ipaming, etc.。

 

Plan name，Renhe Pharmaceutical will invest 320 million yuan to complete the acquisition and transformation of Jiangxi Pharmaceuticals。This is the biggest point of this plan，The purpose of this investment is to achieve Jiangxi Pharmaceutical Holdings，Complete the industrial structure of Renhe Pharmaceutical from OTC faucet to OTC and prescription drug dual -track。

 

Actually，Industry in the industry has long expectations for Renhe Pharmaceutical's advancement prescription medicine。Dongxing Securities has released a survey report.，OTC field is influenced by the market too much，Some risks are not easy to control，Renhe Pharmaceutical is currently in a stable period of development，But because the base is not small，The rapid growth Stake Sports Bettingof the original new varieties stake betting appis unlikely to drive the overall high -speed development，Gradually involved in the prescription drug market is an inevitable choice。

 

This reality is also the concerns of Renhe Pharmaceutical。The reporter learned，The previous series of asset mergers and acquisitions made Renhe Pharmaceutical formed a woman Yan Jie、Youkan、Keck series、Shining eye drops、Six brand series products of positive stomach capsules and Qinghuo Capsules。The product structure of Qingyue OTC makes it quickly become the leader of the industry，But also restricts its pace of further rapid growth。So，Improve the product structure、Entry prescription medicine has always been the wish of Renhe Pharmaceutical。

 

"Now OTC is difficult to cultivate a product of 100 billion yuan，Renhe Pharmaceutical focuses on OTC，Development until now has encountered 'bottleneck'，Although a series of channel integration and business mergers and acquisitions were conducted last year，But the total performance is still lower than market expectations，Therefore, at least the new growth point entered the prescription drug。"" For Dongxing Securities' point of view，A securities analyst in Beijing very agreed。

 

Analyst analysis，Renhe Pharmaceutical acquisition of Jiangxi Pharmaceuticals can get many revenue，Can get a lot of prescription drug products，Improve the product structure and market field，Business risk is shared; at the same time，In the environment of the new medical reform will expand the sales of low -end prescription drugs，Through mergers, it can quickly enter the basic drug market to be optimistic about the industry。

 

An analyst in Shanghai pointed out，Renhe Pharmaceutical continuously purchased and intended to transform，In addition to internal integration, there are risks，Because the strength of Renhe Pharmaceutical Stake Sports Bettinglies in the marketing Stake Sports Bettingof OTC products，The production and sales and channels of prescription drugs are huge different from OTC products，So，The running -in in the future of prescription drugs will be the biggest challenge for its marching prescription drug market。　　

 

or Cheng Jiangxi Pharmaceutical Integration Platform

 

However, the announcement also shows，Plan In addition to the non -PVC soft bag infusion workshop of Jiangxi Pharmaceutical、Popular Pharmaceutical Production Workshop for transformation、Expanded production capacity，It will also invest 20 million yuan for Jiangxi Pharmaceutical Marketing Team、Market outlets to transform。Some people in the industry revealed，Renhe Pharmaceutical has previously acquired several commercial companies specializing in prescription drugs, especially basic drug sales，Just prepare for the basic drug market。

 

There are also industry insiders speculating，Jiangxi Province's relevant departments to use Renhe Pharmaceuticals as a pharmaceutical integration platform for Jiangxi Province，To optimize the industrial structure of Jiangxi's pharmaceutical industry，Improve competitive strength。

 

Renhe Pharmaceutical additional plan is also called，To adjust the structure as the main line，Promoting mergers and reorganization，Cultivate the company into a large enterprise group，Accelerate the technical transformation at the same time，Enhance the quality and international competitiveness of the enterprise; increased the share expansion and investing in Jiangxi Pharmaceuticals will bigger for the company、stronger foundation lays a solid foundation，It is conducive to improving the company's absolute advantage，Consolidate the company in Jiangxi Province、and even the status of the leading market in the country。

 

The aforementioned Shanghai stake sports betting appinstitutional analyst stake betting appalso revealed，Renhe Pharmaceutical Controller Yang Wenlong has always intended to build Renhe Pharmaceutical into a medical leader in Jiangxi Province，and the relevant departments of Jiangxi Province have indeed reported to support the news that Renhe Pharmaceutical is the integration platform，But so far there is still no clear expression。

 

"But，Regardless of whether the benevolent and the end are the platform for integration，According to Yang Wenlong's idea，In the future，Obviously，The integration of Jiangxi Pharmaceutical Industry is gradually opening the prelude。"This Shanghai analyst told reporters。